Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Serum BCMA may be able to serve as a biomarker for predicting outcomes and monitoring patient therapy response in Waldenström macroglobulinemia; positively correlated with β2 and M-protein, negatively with hemoglobin and albumin.”
Title: Serum B-Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients With Waldenström Macroglobulinemia
Authors: Marissa-Skye Goldwater, Jonathan Moore, Sean Bujarski, Ryan Danis, Zakir Khan, Mingjie Li, Stacy Behare, Regina Swift, Marsiye Emamy-Sadr, Benjamin Eades, James R. Berenson
You can read the Full Article in the European Journal of Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
